Altimmune, Inc.
NASDAQ:ALTBiotechnology
+$0.08 today
- Market cap
- $270.48M
- Beta
- 0.23
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$0.73
Volume 4.69M
Average 3.81M
ALT Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Altimmune, Inc.NASDAQ: ALT
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $1.68M rose 7.8% year over year, ahead of the -19.7% change in trailing-twelve-month other income / expenses. Sequentially, it rose 9.5% from the prior quarter. Over 3 fiscal years it compounded at +26.4% a year.
Context
- Other income / expenses amounted to 13939.0% of revenue in FY2025, down 26626.0 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +7.8% holds above the trailing-twelve-month pace of -19.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 5.72M USD
- Year-over-year change
- -29.6%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.72M | -29.6% |
| FY2024 | 2024-12-31 | 8.11M | +8.4% |
| FY2023 | 2023-12-31 | 7.48M | +164.4% |
| FY2022 | 2022-12-31 | 2.83M | +1708.0% |
| FY2021 | 2021-12-31 | (176K) | — |
Other Income / Expenses vs competitors
How ALT compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -19.7% is the 4th highest of 9, against a peer median of -65.6%.
- Other income / expenses amounts to 16213.9% of revenue for ALT, versus a peer median of 10.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $43.71M USD | +6.2% | +388.5% | — | |
| LTM Mar 2026 | $21.62M USD | +427.9% | +121.1% | — | |
| LTM Mar 2026 | $19.31M USD | -71.4% | — | 29.5% | |
| LTM Mar 2026 | $7.16M USD | +37.9% | +80.4% | 10.1% | |
| LTM Mar 2026 | $6.05M USD | -59.8% | — | 3.2% | |
| LTM Mar 2026 | $5.84M USD | -19.7% | +26.4% | 16213.9% | |
| LTM Mar 2026 | -$1.44M USD | -681.1% | — | — | |
| LTM Mar 2026 | -$1.51M USD | -146.9% | +2.8% | 2.2% | |
| FY2025 | -€211.38M EUR | -144.8% | — | 4715.1% | |
| Peer median (excluding ALT) | — | -65.6% | +100.7% | 10.1% | |
Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.41M | (68K) | 426K | 20K | 41K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 4.41M | (68K) | 426K | 20K | 41K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 74.54M | 70.54M | 65.8M | 82.23M | 66.43M |
| Selling, General & Admin | 15.41M | 17.13M | 18.14M | 20.97M | 28.1M |
| Operating Expenses | 101.32M | 87.67M | 96.36M | 103.19M | 94.53M |
| Depreciation & Amortization | 551K | 493K | 477K | 238K | 112K |
| EBITDA | (96.53M) | (84.41M) | (87.94M) | (94.81M) | (87.03M) |
| EBITDA Margin | -2189.0% | 124130.9% | -20642.0% | -474060.0% | -212258.5% |
| Operating Income | (96.91M) | (87.74M) | (95.93M) | (103.17M) | (94.49M) |
| Operating Margin | -2197.6% | 129029.4% | -22518.5% | -515860.0% | -230461.0% |
| Interest Income | 203K | 2.87M | 7.35M | 8.07M | 7.54M |
| Interest Expense | 5K | 8K | 35K | 9K | 1.64M |
| Other Income / Expenses | (176K) | 2.83M | 7.48M | 8.11M | 5.72M |
| Income Before Tax | (97.09M) | (84.91M) | (88.45M) | (95.06M) | (88.77M) |
| Pre-Tax Margin | -2201.6% | 124867.6% | -20762.2% | -475295.0% | -216522.0% |
| Income Tax Expense | 0 | (197K) | 0 | 0 | (681K) |
| Net Income | (97.09M) | (84.71M) | (88.45M) | (95.06M) | (88.09M) |
| Net Margin | -2201.6% | 124577.9% | -20762.2% | -475295.0% | -214861.0% |
| EPS (Basic) | (2.35) | (1.81) | (1.66) | (1.34) | (1.00) |
| EPS (Diluted) | (2.35) | (1.81) | (1.66) | (1.34) | (1.00) |
| Weighted Avg Shares | 41.28M | 46.93M | 53.25M | 71M | 88.1M |
| Weighted Avg Shares (Diluted) | 41.28M | 46.93M | 53.25M | 71M | 88.1M |
Altimmune, Inc.
NASDAQ:ALT
Intrinsic Alpha fair value
Locked
Current Price
$1.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.